First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience. Mediterr J Hematol Infect Dis [Internet]. 2026 Sep. 1 [cited 2026 Sep. 2];18(1):e2026066. Available from: https://www.mjhid.org/mjhid/article/view/6449